JP2011506480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506480A5 JP2011506480A5 JP2010538205A JP2010538205A JP2011506480A5 JP 2011506480 A5 JP2011506480 A5 JP 2011506480A5 JP 2010538205 A JP2010538205 A JP 2010538205A JP 2010538205 A JP2010538205 A JP 2010538205A JP 2011506480 A5 JP2011506480 A5 JP 2011506480A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- piperidin
- carboxamide
- pyrido
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 347
- 150000001875 compounds Chemical class 0.000 claims description 116
- -1 Tetrahydro-2H-pyran-4-yl Chemical group 0.000 claims description 62
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 150000003857 carboxamides Chemical class 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 150000001204 N-oxides Chemical class 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- RCFJOZXVZXSWCF-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-(4-fluorophenyl)sulfonylpiperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1N1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=CC(F)=CC=3)=C2CC1 RCFJOZXVZXSWCF-UHFFFAOYSA-N 0.000 claims description 2
- DUUPPYOMJAHZDS-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1N1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=NC=CC=4)CC3)=C2CC1 DUUPPYOMJAHZDS-UHFFFAOYSA-N 0.000 claims description 2
- CVBNRTBWRXYMNS-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-(pyridine-3-carbonyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1N1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)C(=O)C=3C=NC=CC=3)=C2CC1 CVBNRTBWRXYMNS-UHFFFAOYSA-N 0.000 claims description 2
- HZRXZLQFFZLOCG-UHFFFAOYSA-N 2-[(4-carbamoylphenyl)methyl]-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=CN=CC=4)CC3)=C2CC1 HZRXZLQFFZLOCG-UHFFFAOYSA-N 0.000 claims description 2
- NAMXHYMYXYEIIH-UHFFFAOYSA-N 2-[(4-carbamoylphenyl)methyl]-n-[1-(pyridine-4-carbonyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)C(=O)C=3C=CN=CC=3)=C2CC1 NAMXHYMYXYEIIH-UHFFFAOYSA-N 0.000 claims description 2
- OTGWQCQKDUIEOE-UHFFFAOYSA-N 2-[(4-carbamoylphenyl)methyl]-n-[1-[(4-carbamoylphenyl)methyl]piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(=O)N)=CC=C1CN1CCC(NC(=O)C=2C=C3C=4CN(CC=5C=CC(=CC=5)C(N)=O)CCC=4NC3=CC=2)CC1 OTGWQCQKDUIEOE-UHFFFAOYSA-N 0.000 claims description 2
- ZQCSYMFYGXRFIJ-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=NC=CC=4)CC3)=C2CC1 ZQCSYMFYGXRFIJ-UHFFFAOYSA-N 0.000 claims description 2
- NIKUVLNQFKYFIN-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-n-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=CC(=CC=4)C(F)(F)F)CC3)=C2CC1 NIKUVLNQFKYFIN-UHFFFAOYSA-N 0.000 claims description 2
- XLSJCVMIRMANEV-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound FC(C1=CC=C(CN2CC3=C(NC=4C=CC(=CC3=4)C(=O)N)CC2)C=C1)(F)F XLSJCVMIRMANEV-UHFFFAOYSA-N 0.000 claims description 2
- BKBLCVYZVFFSLX-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methyl]-n-[1-[3-(trifluoromethyl)phenyl]sulfonylpiperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=C(C=CC=3)C(F)(F)F)=C2CC1 BKBLCVYZVFFSLX-UHFFFAOYSA-N 0.000 claims description 2
- KOEFDTDROGKCAT-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methyl]-n-[1-[4-(trifluoromethyl)phenyl]sulfonylpiperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)=C2CC1 KOEFDTDROGKCAT-UHFFFAOYSA-N 0.000 claims description 2
- ORJZEXQGPICXJF-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methyl]-n-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=C3C=4CN(CC=5C=CC(=CC=5)C(F)(F)F)CCC=4NC3=CC=2)CC1 ORJZEXQGPICXJF-UHFFFAOYSA-N 0.000 claims description 2
- BTAIFWSROFGMFY-UHFFFAOYSA-N 2-benzyl-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2NC=3CCN(CC=4C=CC=CC=4)CC=3C2=CC=1C(=O)NC(CC1)CCN1CC1=CC=NC=C1 BTAIFWSROFGMFY-UHFFFAOYSA-N 0.000 claims description 2
- YNQXJGXMYJSKIK-UHFFFAOYSA-N 2-benzyl-n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2NC=3CCN(CC=4C=CC=CC=4)CC=3C2=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 YNQXJGXMYJSKIK-UHFFFAOYSA-N 0.000 claims description 2
- PSAKFAMEEFCYHR-UHFFFAOYSA-N 2-benzyl-n-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CCC(NC(=O)C=2C=C3C=4CN(CC=5C=CC=CC=5)CCC=4NC3=CC=2)CC1 PSAKFAMEEFCYHR-UHFFFAOYSA-N 0.000 claims description 2
- LRWUVKQKCAKBSO-UHFFFAOYSA-N 4-[(4-benzylpiperazin-1-yl)methyl]-N-(1-benzylpiperidin-4-yl)benzamide N-(1-benzylpiperidin-4-yl)-4-[[4-(cyclohexylmethyl)piperazin-1-yl]methyl]benzamide Chemical compound O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(CN2CCN(CC3CCCCC3)CC2)cc1.O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc(CN2CCN(Cc3ccccc3)CC2)cc1 LRWUVKQKCAKBSO-UHFFFAOYSA-N 0.000 claims description 2
- NOEUVPVQVYUNNQ-UHFFFAOYSA-N 4-[(4-benzylpiperazin-1-yl)methyl]-n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]benzamide Chemical compound C=1C=C(CN2CCN(CC=3C=CC=CC=3)CC2)C=CC=1C(=O)NC(CC1)CCN1CC1=CC=CN=C1 NOEUVPVQVYUNNQ-UHFFFAOYSA-N 0.000 claims description 2
- YSWUPDVHCQKFEB-UHFFFAOYSA-N 4-[(4-benzylpiperazin-1-yl)methyl]-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]benzamide Chemical compound C=1C=C(CN2CCN(CC=3C=CC=CC=3)CC2)C=CC=1C(=O)NC(CC1)CCN1CC1=CC=NC=C1 YSWUPDVHCQKFEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- MRHVTROBWROWAO-UHFFFAOYSA-N 5-acetyl-n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)NC4CCN(CC=5C=NC=CC=5)CC4)=CC=C3N(C(=O)C)C=2CCN1CC1=CC=C(C(F)(F)F)C=C1 MRHVTROBWROWAO-UHFFFAOYSA-N 0.000 claims description 2
- KGFAHANRXJLCME-UHFFFAOYSA-N 5-methyl-2-[[4-(trifluoromethyl)phenyl]methyl]-n-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)NC4CCN(CC=5C=CC(=CC=5)C(F)(F)F)CC4)=CC=C3N(C)C=2CCN1CC1=CC=C(C(F)(F)F)C=C1 KGFAHANRXJLCME-UHFFFAOYSA-N 0.000 claims description 2
- PVXROYBDZVXUHK-UHFFFAOYSA-N 5-methyl-n,2-bis(oxan-4-yl)-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2N(C)C=3CCN(C4CCOCC4)CC=3C2=CC=1C(=O)NC1CCOCC1 PVXROYBDZVXUHK-UHFFFAOYSA-N 0.000 claims description 2
- IGGLLQQALORMSZ-UHFFFAOYSA-N 5-methyl-n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)NC4CCN(CC=5C=NC=CC=5)CC4)=CC=C3N(C)C=2CCN1CC1=CC=C(C(F)(F)F)C=C1 IGGLLQQALORMSZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- YAJPXWSUYALXJQ-UHFFFAOYSA-N C=1C=CC=CC=1C(C)N(CC1)CCC1NC(=O)C(C=C1C=2C3)=CC=C1NC=2CCN3CC1=CC=C(C(F)(F)F)C=C1 Chemical compound C=1C=CC=CC=1C(C)N(CC1)CCC1NC(=O)C(C=C1C=2C3)=CC=C1NC=2CCN3CC1=CC=C(C(F)(F)F)C=C1 YAJPXWSUYALXJQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- NEVHNIWAXGKTBI-UHFFFAOYSA-N O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc2cc(OC3CCN(Cc4ccc(cc4)C#N)CC3)ccc2c1.FC(F)(F)c1ccc(cc1)N1CCC(CC1)Oc1ccc2cc(ccc2c1)C(=O)NC1CCN(Cc2ccccc2)CC1 Chemical compound O=C(NC1CCN(Cc2ccccc2)CC1)c1ccc2cc(OC3CCN(Cc4ccc(cc4)C#N)CC3)ccc2c1.FC(F)(F)c1ccc(cc1)N1CCC(CC1)Oc1ccc2cc(ccc2c1)C(=O)NC1CCN(Cc2ccccc2)CC1 NEVHNIWAXGKTBI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 2
- CPBDISFQIOZKMH-UHFFFAOYSA-N benzyl 8-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]carbamoyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC(=O)C1=CC=C(NC2=C3CN(CC2)C(=O)OCC=2C=CC=CC=2)C3=C1 CPBDISFQIOZKMH-UHFFFAOYSA-N 0.000 claims description 2
- OKBRVRYLWWQBQY-UHFFFAOYSA-N benzyl 8-[[1-[(4-cyanophenyl)methyl]piperidin-4-yl]carbamoyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carboxylate Chemical compound C1CC=2NC3=CC=C(C(=O)NC4CCN(CC=5C=CC(=CC=5)C#N)CC4)C=C3C=2CN1C(=O)OCC1=CC=CC=C1 OKBRVRYLWWQBQY-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- DQIKAHYIEHONKP-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-4-[[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methyl]benzamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CCN(CC=2C=CC(=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)CC1 DQIKAHYIEHONKP-UHFFFAOYSA-N 0.000 claims description 2
- HDMYUOJFXJMKSY-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]oxynaphthalene-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CCC(OC=2C=C3C=CC(=CC3=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)CC1 HDMYUOJFXJMKSY-UHFFFAOYSA-N 0.000 claims description 2
- WMIYKDUKJBRSAZ-UHFFFAOYSA-N n-(1-pyridin-3-ylsulfonylpiperidin-4-yl)-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=NC=CC=3)=C2CC1 WMIYKDUKJBRSAZ-UHFFFAOYSA-N 0.000 claims description 2
- IMRVWWJADBDGBL-UHFFFAOYSA-N n-[1-(1,3-oxazol-4-ylmethyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4N=COC=4)CC3)=C2CC1 IMRVWWJADBDGBL-UHFFFAOYSA-N 0.000 claims description 2
- FZGINFUBHSEKDV-UHFFFAOYSA-N n-[1-(3-cyanophenyl)sulfonylpiperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=C(C=CC=3)C#N)=C2CC1 FZGINFUBHSEKDV-UHFFFAOYSA-N 0.000 claims description 2
- BCFVDNBHVMIRAB-UHFFFAOYSA-N n-[1-(4-cyanophenyl)sulfonylpiperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)S(=O)(=O)C=3C=CC(=CC=3)C#N)=C2CC1 BCFVDNBHVMIRAB-UHFFFAOYSA-N 0.000 claims description 2
- AVMQVXRALLUWAU-UHFFFAOYSA-N n-[1-(4-fluorophenyl)sulfonylpiperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC(NC(=O)C=2C=C3C=4CN(CC=5C=CC(=CC=5)C(F)(F)F)CCC=4NC3=CC=2)CC1 AVMQVXRALLUWAU-UHFFFAOYSA-N 0.000 claims description 2
- CDVFXBMESJKDMD-UHFFFAOYSA-N n-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=NC=CC=4)CC3)=C2CC1 CDVFXBMESJKDMD-UHFFFAOYSA-N 0.000 claims description 2
- IKBHQVYRGCPXOB-UHFFFAOYSA-N n-[1-(pyridine-4-carbonyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)C(=O)C=3C=CN=CC=3)=C2CC1 IKBHQVYRGCPXOB-UHFFFAOYSA-N 0.000 claims description 2
- OGFRKPNRHFGFMY-UHFFFAOYSA-N n-[1-[(1-methylimidazol-4-yl)methyl]piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound CN1C=NC(CN2CCC(CC2)NC(=O)C=2C=C3C=4CN(CC=5C=CC(=CC=5)C(F)(F)F)CCC=4NC3=CC=2)=C1 OGFRKPNRHFGFMY-UHFFFAOYSA-N 0.000 claims description 2
- MJZXWUSXZLKVPF-UHFFFAOYSA-N n-[1-[(3-fluorophenyl)carbamoyl]piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound FC1=CC=CC(NC(=O)N2CCC(CC2)NC(=O)C=2C=C3C=4CN(CC=5C=CC(=CC=5)C(F)(F)F)CCC=4NC3=CC=2)=C1 MJZXWUSXZLKVPF-UHFFFAOYSA-N 0.000 claims description 2
- VNYBAYCVTPQDHT-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-2-(4-cyanophenyl)sulfonyl-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2NC=3CCN(S(=O)(=O)C=4C=CC(=CC=4)C#N)CC=3C2=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 VNYBAYCVTPQDHT-UHFFFAOYSA-N 0.000 claims description 2
- KKNPTVYJOMDBSC-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-2-[4-(trifluoromethyl)phenyl]sulfonyl-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=CC(=CC=4)C#N)CC3)=C2CC1 KKNPTVYJOMDBSC-UHFFFAOYSA-N 0.000 claims description 2
- ROWAZKLYSMMAGD-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-5-methyl-2-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-1h-pyrido[4,3-b]indole-8-carboxamide Chemical compound C1C=2C3=CC(C(=O)NC4CCN(CC=5C=CC(=CC=5)C#N)CC4)=CC=C3N(C)C=2CCN1CC1=CC=C(C(F)(F)F)C=C1 ROWAZKLYSMMAGD-UHFFFAOYSA-N 0.000 claims description 2
- UTBCSRCIYLJRPJ-UHFFFAOYSA-N n-[1-[[4-(trifluoromethyl)phenyl]carbamoyl]piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)C(=O)NC=3C=CC(=CC=3)C(F)(F)F)=C2CC1 UTBCSRCIYLJRPJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- CPMFDFYIVGIAOS-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)carbamoyl]piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC3)C(=O)NC=3C=CC(=CC=3)C#N)=C2CC1 CPMFDFYIVGIAOS-UHFFFAOYSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 description 40
- 125000004093 cyano group Chemical group *C#N 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 6
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- VNWKTOKETHGBQD-AKLPVKDBSA-N carbane Chemical compound [15CH4] VNWKTOKETHGBQD-AKLPVKDBSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 0 C*(CC(*)C1)N(*)CC*1Oc(cc1)cc(cc2)c1cc2C(N(*)*)=O Chemical compound C*(CC(*)C1)N(*)CC*1Oc(cc1)cc(cc2)c1cc2C(N(*)*)=O 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- MEOZZMQRECNWJP-UHFFFAOYSA-N NC(C(C=C1)=CC2=C1NC1=C2C(C(CC2)CCN2C(NC(C=C2)=CC=C2C#N)=O)N(CC2=CC=C(C(F)(F)F)C=C2)CC1)=O Chemical compound NC(C(C=C1)=CC2=C1NC1=C2C(C(CC2)CCN2C(NC(C=C2)=CC=C2C#N)=O)N(CC2=CC=C(C(F)(F)F)C=C2)CC1)=O MEOZZMQRECNWJP-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- QZHFEQWZBUYFQQ-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-5-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]oxy-1h-indole-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCC(OC=2C=C3C=C(NC3=CC=2)C(=O)NC2CCN(CC=3C=CC=CC=3)CC2)CC1 QZHFEQWZBUYFQQ-UHFFFAOYSA-N 0.000 description 1
- DGECFLNJVHGQCN-UHFFFAOYSA-N n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-2-[[4-(trifluoromethyl)phenyl]methyl]-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CN1CC(C2=CC(=CC=C2N2)C(=O)NC3CCN(CC=4C=CN=CC=4)CC3)=C2CC1 DGECFLNJVHGQCN-UHFFFAOYSA-N 0.000 description 1
- LCPUAANFKRLRTA-UHFFFAOYSA-N n-[1-[(4-cyanophenyl)methyl]piperidin-4-yl]-2-pyridin-3-ylsulfonyl-1,3,4,5-tetrahydropyrido[4,3-b]indole-8-carboxamide Chemical compound C=1C=C2NC=3CCN(S(=O)(=O)C=4C=NC=CC=4)CC=3C2=CC=1C(=O)NC(CC1)CCN1CC1=CC=C(C#N)C=C1 LCPUAANFKRLRTA-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1311407P | 2007-12-12 | 2007-12-12 | |
| US1312407P | 2007-12-12 | 2007-12-12 | |
| US61/013,114 | 2007-12-12 | ||
| US61/013,124 | 2007-12-12 | ||
| US1640607P | 2007-12-21 | 2007-12-21 | |
| US1640507P | 2007-12-21 | 2007-12-21 | |
| US1640207P | 2007-12-21 | 2007-12-21 | |
| US61/016,406 | 2007-12-21 | ||
| US61/016,402 | 2007-12-21 | ||
| US61/016,405 | 2007-12-21 | ||
| US7820908P | 2008-07-03 | 2008-07-03 | |
| US61/078,209 | 2008-07-03 | ||
| PCT/US2008/086673 WO2009076631A1 (en) | 2007-12-12 | 2008-12-12 | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506480A JP2011506480A (ja) | 2011-03-03 |
| JP2011506480A5 true JP2011506480A5 (OSRAM) | 2012-01-26 |
| JP5650540B2 JP5650540B2 (ja) | 2015-01-07 |
Family
ID=40364381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538205A Expired - Fee Related JP5650540B2 (ja) | 2007-12-12 | 2008-12-12 | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8129390B2 (OSRAM) |
| EP (1) | EP2231666B1 (OSRAM) |
| JP (1) | JP5650540B2 (OSRAM) |
| CA (1) | CA2707047C (OSRAM) |
| ES (1) | ES2553340T3 (OSRAM) |
| WO (1) | WO2009076631A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| MX2010005298A (es) * | 2007-11-16 | 2010-06-30 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| EP3536336A1 (en) * | 2007-11-30 | 2019-09-11 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
| EP2231666B1 (en) * | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| AU2009240643B2 (en) | 2008-04-23 | 2014-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
| WO2010088392A1 (en) * | 2009-01-28 | 2010-08-05 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds and methods for using the same |
| CN102459249A (zh) | 2009-05-22 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法 |
| GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
| WO2011032320A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Novel alkene oxindole derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011123681A1 (en) | 2010-03-31 | 2011-10-06 | Rigel Pharmaceuticals, Inc. | Methods for using carboxamide, sulfonamide and amine compounds |
| WO2011142359A1 (ja) * | 2010-05-10 | 2011-11-17 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| PT2598483T (pt) * | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| US9005909B2 (en) | 2011-01-06 | 2015-04-14 | Rigel Pharmaceuticals, Inc. | Whole blood assay for measuring AMPK activation |
| JP2014507452A (ja) | 2011-03-07 | 2014-03-27 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | キノリン誘導体 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2759533B1 (en) * | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013116491A1 (en) * | 2012-02-01 | 2013-08-08 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using them |
| JP6664632B2 (ja) * | 2013-09-30 | 2020-03-13 | 国立大学法人 東京大学 | アディポネクチン受容体活性化化合物 |
| WO2017103851A1 (en) * | 2015-12-17 | 2017-06-22 | Astex Therapeutics Limited | Quinoline-3-carboxamides as h-pgds inhibitors |
| RU2732075C1 (ru) * | 2019-07-24 | 2020-09-11 | Федеральное государственное бюджетное учреждение науки Институт аналитического приборостроения Российской академии наук | Способ предварительной сепарации потока заряженных частиц в источнике ионов с ионизацией при атмосферном давлении |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028A (en) * | 1847-03-20 | monohot | ||
| DE3382687D1 (de) * | 1982-09-30 | 1993-07-01 | Ciba Geigy Ag | Mit bis-(polyalkylpiperidinyl-amino)-1,3,5-triazinen stabilisierte polyolefine. |
| GB8820115D0 (en) | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| US5216156A (en) * | 1992-05-05 | 1993-06-01 | Ciba-Geigy Corporation | Non-migrating 1-hydrocarbyloxy-2,2,6,6-tetramethylpiperidine 1,3,5-triazine derivatives |
| US6137002A (en) | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
| US5994344A (en) | 1996-03-28 | 1999-11-30 | Glaxo Wellcome Inc. | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| GB9715584D0 (en) | 1997-07-23 | 1997-10-01 | Eisai Co Ltd | Compounds |
| DE19738615A1 (de) | 1997-09-04 | 1999-03-11 | Clariant Gmbh | Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| BR9913654A (pt) | 1998-08-28 | 2001-11-27 | Scios Inc | Inibidores de p-38alfa quinase |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| PT1218380E (pt) | 1999-10-08 | 2004-05-31 | Gruenenthal Gmbh | Derivados de imidazo-3-il-amina biciclicos substituidos no anel de seis membros |
| US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US6579328B2 (en) * | 2000-05-01 | 2003-06-17 | Ciba Specialty Chemicals Corporation | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| CA2445923A1 (en) | 2001-05-10 | 2002-11-14 | Abbott Gmbh & Co. Kg | Arylsulfonamide ethers, and methods of use thereof |
| WO2002094796A2 (en) * | 2001-05-18 | 2002-11-28 | Axxima Pharmaceuticals Ag | Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| WO2003022856A1 (en) | 2001-09-12 | 2003-03-20 | Pharmacia & Upjohn Company | Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases |
| TW200407307A (en) * | 2001-11-26 | 2004-05-16 | Ciba Sc Holding Ag | Process for the synthesis of amine ethers from secondary amino oxides |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| WO2003072578A1 (en) | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| GB0314054D0 (en) | 2003-06-17 | 2003-07-23 | Pfizer Ltd | Amide derivatives as selective serotonin re-uptake inhibitors |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| BRPI0417156A (pt) * | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| US7544803B2 (en) | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
| JP4594386B2 (ja) * | 2004-06-02 | 2010-12-08 | エフ．ホフマン−ラ ロシュ アーゲー | ヒスタミン３受容体のリガンドとして有用なナフタレン誘導体 |
| DK1761519T3 (da) | 2004-06-21 | 2008-07-21 | Hoffmann La Roche | Indolderivater som histaminreceptorantagonister |
| RU2391338C2 (ru) | 2004-10-19 | 2010-06-10 | Ф.Хоффманн-Ля Рош Аг | Производные хинолина |
| MX2007004862A (es) | 2004-10-29 | 2007-05-09 | Astrazeneca Ab | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias. |
| JP4935357B2 (ja) | 2004-11-08 | 2012-05-23 | Ｍｓｄ株式会社 | 新規縮環イミダゾール誘導体 |
| JP2008521862A (ja) | 2004-12-01 | 2008-06-26 | デブジェン エヌブイ | イオンチャンネル、特にｋｖファミリーのイオンチャンネルと相互作用する５−カルボキサミド置換チアゾール誘導体 |
| EP1838312A4 (en) | 2004-12-17 | 2010-01-20 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| EA014956B1 (ru) | 2004-12-17 | 2011-04-29 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| EP1844023A1 (en) * | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| WO2006094235A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| US7893267B2 (en) | 2005-03-14 | 2011-02-22 | High Point Pharmaceuticals, Llc | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors |
| EP1863810A4 (en) * | 2005-03-22 | 2010-03-31 | Astrazeneca Ab | NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| WO2007005951A2 (en) | 2005-07-05 | 2007-01-11 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| WO2007007688A1 (ja) * | 2005-07-08 | 2007-01-18 | Mochida Pharmaceutical Co., Ltd. | ３,５－ジアミノ－１,２,４－トリアゾール誘導体 |
| CN101263125A (zh) * | 2005-07-15 | 2008-09-10 | 先灵公司 | 用于癌症治疗的喹唑啉衍生物 |
| ES2384643T3 (es) * | 2005-11-30 | 2012-07-10 | Astellas Pharma Inc. | Derivados de 2-aminobenzamida como inhibidores del receptor vainilloide 1 (VR1) útiles para el tratamiento del dolor o el trastorno de la función de la vejiga |
| EP1960383B1 (en) | 2005-11-30 | 2010-04-28 | F. Hoffmann-la Roche AG | 5-substituted indole-2-carboxamide derivatives |
| EP1968967B1 (en) | 2005-11-30 | 2011-04-27 | F. Hoffmann-La Roche AG | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
| BRPI0619268A2 (pt) | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
| KR20080080201A (ko) | 2005-12-21 | 2008-09-02 | 쉐링 코포레이션 | 히스타민 ｈ3 길항제로서 유용한 치환된 아닐린 유도체 |
| EP1984375A2 (en) | 2006-01-25 | 2008-10-29 | Smithkline Beecham Corporation | Chemical compounds |
| EP1984376A4 (en) | 2006-01-25 | 2009-04-08 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US20090036429A1 (en) | 2006-02-17 | 2009-02-05 | Ohler Norman E | Hydroxypiperidine Derivatives and Uses Thereof |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| CA2647440A1 (en) * | 2006-04-12 | 2007-10-18 | Matthias Nettekoven | 5-amido-2-carboxamide indoles |
| ES2487967T3 (es) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JP2009539885A (ja) | 2006-06-13 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体 |
| TW200821303A (en) | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| EP2079694B1 (en) * | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| EP2141994A4 (en) * | 2007-04-26 | 2011-05-18 | Avalon Pharmaceuticals | POLYCYCLIC COMPOUNDS AND USES THEREOF |
| SI2074120T1 (sl) * | 2007-10-25 | 2010-06-30 | Exelixis Inc | Tropan spojine |
| MX2010005298A (es) * | 2007-11-16 | 2010-06-30 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| EP2231666B1 (en) | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| AU2009240643B2 (en) * | 2008-04-23 | 2014-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide compounds for the treatment of metabolic disorders |
-
2008
- 2008-12-12 EP EP08860063.0A patent/EP2231666B1/en not_active Not-in-force
- 2008-12-12 CA CA2707047A patent/CA2707047C/en active Active
- 2008-12-12 US US12/334,201 patent/US8129390B2/en active Active
- 2008-12-12 JP JP2010538205A patent/JP5650540B2/ja not_active Expired - Fee Related
- 2008-12-12 WO PCT/US2008/086673 patent/WO2009076631A1/en not_active Ceased
- 2008-12-12 ES ES08860063.0T patent/ES2553340T3/es active Active
-
2012
- 2012-01-11 US US13/348,384 patent/US8557822B2/en not_active Expired - Fee Related
-
2013
- 2013-10-14 US US14/053,328 patent/US8895578B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506480A5 (OSRAM) | ||
| JP2011503210A5 (OSRAM) | ||
| JP4719745B2 (ja) | カリウムチャンネル阻害剤 | |
| JP6012735B2 (ja) | 新規ジヒドロキノリン−２−オン誘導体 | |
| CN103038229B (zh) | 杂芳基化合物及其使用方法 | |
| EP2542076B1 (en) | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders | |
| JP2011527665A5 (OSRAM) | ||
| KR20230094196A (ko) | Mtap-결핍 및/또는 mta 축적 암의 치료에 유용한 피페리딘-1-일-n-피리딘-3-일-2-옥소아세트아마이드 유도체 | |
| JP2023530848A (ja) | タンパク質を標的とし、分解するための化合物ならびにその調製方法および使用 | |
| US9266881B2 (en) | Triazolopyridinone PDE10 inhibitors | |
| JP2025061147A (ja) | Ｔｙｋ２阻害剤およびその使用 | |
| JP2010514788A5 (OSRAM) | ||
| EP2434885B1 (en) | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors | |
| JP2014518223A (ja) | 化合物とその治療用途 | |
| JP2013532692A5 (OSRAM) | ||
| JP2014051516A (ja) | タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体 | |
| TW201215602A (en) | Novel nicotinamide derivative or salt thereof | |
| EP3319966B1 (en) | Bicyclic heterocyclic compounds as pde2 inhibitors | |
| TW200823188A (en) | Certain chemical entities, compositions, and methods | |
| KR20100088142A (ko) | 비-뉴클레오사이드 역전사효소 억제제 | |
| TW201217362A (en) | Heteroaryls and uses thereof | |
| JP2012516349A5 (OSRAM) | ||
| US20130225583A1 (en) | Substituted amino-triazolyl pde10 inhibitors | |
| TW202509031A (zh) | Ｃｄｋ抑制劑萘啶化合物 | |
| WO2014081617A1 (en) | Substituted pyridone derivatives as pde10 inhibitors |